TARS

$0.00

(

+0.00%

)
Quote details

stock

Tarsus Pharmaceuticals Inc

NASDAQ | TARS

74.97

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 16, 2025)

$3.16B

Market Cap

-

P/E Ratio

-2.29

EPS

$76.81

52 Week High

$35.84

52 Week Low

HEALTHCARE

Sector

TARS Chart

Recent Chart
Price Action

TARS Technicals

Tags:

TARS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $170M
Total Revenue $183M
Cost Of Revenue $13M
Costof Goods And Services Sold $13M
Operating Income -$121M
Selling General And Administrative $237M
Research And Development $53M
Operating Expenses $291M
Investment Income Net -
Net Interest Income $7.2M
Interest Income $15M
Interest Expense $7.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.2M
Income Before Tax -$116M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$116M
Comprehensive Income Net Of Tax -
Ebit -$108M
Ebitda -$106M
Net Income -$116M

Revenue & Profitability

Earnings Performance

TARS Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $377M
Total Current Assets $357M
Cash And Cash Equivalents At Carrying Value $95M
Cash And Short Term Investments $95M
Inventory $2.6M
Current Net Receivables $48M
Total Non Current Assets $20M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $8.3M
Intangible Assets Excluding Goodwill $8.3M
Goodwill -
Investments -
Long Term Investments $3M
Short Term Investments $197M
Other Current Assets $15M
Other Non Current Assets -
Total Liabilities $152M
Total Current Liabilities $81M
Current Accounts Payable $28M
Deferred Revenue -
Current Debt -
Short Term Debt $608K
Total Non Current Liabilities $72M
Capital Lease Obligations $608K
Long Term Debt $72M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $72M
Other Current Liabilities $52M
Other Non Current Liabilities -
Total Shareholder Equity $225M
Treasury Stock -
Retained Earnings -$360M
Common Stock $6K
Common Stock Shares Outstanding $38M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$83M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.2M
Capital Expenditures $1.6M
Change In Receivables -
Change In Inventory -$2M
Profit Loss -
Cashflow From Investment -$199M
Cashflow From Financing $155M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$116M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $170M
Total Revenue $183M
Cost Of Revenue $13M
Costof Goods And Services Sold $13M
Operating Income -$121M
Selling General And Administrative $237M
Research And Development $53M
Operating Expenses $291M
Investment Income Net -
Net Interest Income $7.2M
Interest Income $15M
Interest Expense $7.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.2M
Income Before Tax -$116M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$116M
Comprehensive Income Net Of Tax -
Ebit -$108M
Ebitda -$106M
Net Income -$116M

TARS News

TARS Profile

Tarsus Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Irvine, California, dedicated to advancing innovative therapeutic candidates specifically targeting ophthalmic diseases. With a pipeline centered around groundbreaking treatments for conditions such as dry eye disease and other vision-related disorders, Tarsus aims to fill significant unmet medical needs in the ophthalmic market. The company's commitment to robust clinical development supports its mission to enhance patient outcomes and drive long-term growth.

VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
YYAI
-10.71%
$0.12
BURU
+1.09%
$0.34
RXRX
-6.33%
$6.36
EPWK
+26.46%
$0.09
BITF
-18.39%
$5.28
IVF
+85.67%
$1.40
NAYA
+85.67%
$1.40
CGBS
-39.47%
$0.03
NVDA
+1.10%
$181.81
PLUG
-8.70%
$3.51
YDKG
-49.73%
$0.09
ADAP
+6.02%
$0.19
BYND
-22.39%
$0.52
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
NIO
-1.09%
$6.74
MIRA
+36.36%
$1.80
F
-0.17%
$11.74
SCNX
-17.63%
$0.58
BBD
+1.71%
$3.25
AADI
+24.28%
$2.61
KVUE
-13.22%
$14.11
ACHR
-8.90%
$11.87
INTC
-0.83%
$36.84
TLRY
-8.33%
$1.54
HPE
-10.06%
$22.52
FEMY
+35.37%
$0.74
TSLA
-1.47%
$428.75
IONZ
+19.44%
$3.44
SOFI
-5.10%
$26.60
ONDS
-13.77%
$8.19
CAN
-14.79%
$1.67
AMD
-1.69%
$234.56
DFLI
-32.48%
$1.33
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.56%
$3.22
AAL
-4.88%
$11.89
CLF
-2.79%
$13.56
MARA
-11.27%
$20.26
GDXD
-10.23%
$0.60
BTG
+4.76%
$5.94
LAES
-15.08%
$6.36
AMC
-2.30%
$2.75
BTBT
-9.11%
$3.69
RF
-5.61%
$23.35
GNPX
-43.39%
$0.47
QBTS
-9.64%
$40.46
VSEE
-13.85%
$0.51
QS
-13.38%
$15.46
RR
-7.95%
$5.67
GPUS
-5.78%
$0.36
LGCB
+19.39%
$1.97
NAK
-15.15%
$2.24
ABAT
-36.64%
$5.67
HBAN
-5.18%
$15.37
SNAP
-1.89%
$7.76
QUBT
-11.72%
$18.73
QSI
-3.42%
$2.54
CIFR
-10.98%
$18.72
RGTZ
+29.08%
$11.23
WOK
+1.55%
$0.05
CRML
-14.52%
$19.42
UUUU
-13.20%
$21.69
CLSK
-13.83%
$19.98
IREN
-9.04%
$61.83
ASST
-6.24%
$0.90
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
KEY
-5.35%
$16.78
T
+0.49%
$26.20
PLTR
-0.83%
$178.12
SOUN
-2.99%
$20.76
AMZN
-0.51%
$214.47
MU
+5.51%
$202.53
JBLU
-3.63%
$4.76
APLD
-2.96%
$36.64
SMR
-10.87%
$47.62
FNB
-7.21%
$14.65
WTO
-88.87%
$0.13
RMBL
+60.50%
$3.21
GRAB
-3.54%
$5.71
AAPL
-0.75%
$247.45
WULF
-10.40%
$13.86
NOK
+0.35%
$5.67
ADD
-25.47%
$0.05
HIMS
-5.75%
$59.15
AUUD
+0.97%
$2.06
SOND
+79.34%
$1.65
BAC
-4.03%
$50.17
CRWV
+1.79%
$141.74
JOBY
-8.69%
$16.07
SLNH
-2.33%
$4.19
IONQ
-9.41%
$65.59
TOVX
-48.67%
$0.43
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
YYAI
-10.71%
$0.12
BURU
+1.09%
$0.34
RXRX
-6.33%
$6.36
EPWK
+26.46%
$0.09
BITF
-18.39%
$5.28
IVF
+85.67%
$1.40
NAYA
+85.67%
$1.40
CGBS
-39.47%
$0.03
NVDA
+1.10%
$181.81
PLUG
-8.70%
$3.51
YDKG
-49.73%
$0.09
ADAP
+6.02%
$0.19
BYND
-22.39%
$0.52
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
NIO
-1.09%
$6.74
MIRA
+36.36%
$1.80
F
-0.17%
$11.74
SCNX
-17.63%
$0.58
BBD
+1.71%
$3.25
AADI
+24.28%
$2.61
KVUE
-13.22%
$14.11
ACHR
-8.90%
$11.87
INTC
-0.83%
$36.84
TLRY
-8.33%
$1.54
HPE
-10.06%
$22.52
FEMY
+35.37%
$0.74
TSLA
-1.47%
$428.75
IONZ
+19.44%
$3.44
SOFI
-5.10%
$26.60
ONDS
-13.77%
$8.19
CAN
-14.79%
$1.67
AMD
-1.69%
$234.56
DFLI
-32.48%
$1.33
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.56%
$3.22
AAL
-4.88%
$11.89
CLF
-2.79%
$13.56
MARA
-11.27%
$20.26
GDXD
-10.23%
$0.60
BTG
+4.76%
$5.94
LAES
-15.08%
$6.36
AMC
-2.30%
$2.75
BTBT
-9.11%
$3.69
RF
-5.61%
$23.35
GNPX
-43.39%
$0.47
QBTS
-9.64%
$40.46
VSEE
-13.85%
$0.51
QS
-13.38%
$15.46
RR
-7.95%
$5.67
GPUS
-5.78%
$0.36
LGCB
+19.39%
$1.97
NAK
-15.15%
$2.24
ABAT
-36.64%
$5.67
HBAN
-5.18%
$15.37
SNAP
-1.89%
$7.76
QUBT
-11.72%
$18.73
QSI
-3.42%
$2.54
CIFR
-10.98%
$18.72
RGTZ
+29.08%
$11.23
WOK
+1.55%
$0.05
CRML
-14.52%
$19.42
UUUU
-13.20%
$21.69
CLSK
-13.83%
$19.98
IREN
-9.04%
$61.83
ASST
-6.24%
$0.90
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
KEY
-5.35%
$16.78
T
+0.49%
$26.20
PLTR
-0.83%
$178.12
SOUN
-2.99%
$20.76
AMZN
-0.51%
$214.47
MU
+5.51%
$202.53
JBLU
-3.63%
$4.76
APLD
-2.96%
$36.64
SMR
-10.87%
$47.62
FNB
-7.21%
$14.65
WTO
-88.87%
$0.13
RMBL
+60.50%
$3.21
GRAB
-3.54%
$5.71
AAPL
-0.75%
$247.45
WULF
-10.40%
$13.86
NOK
+0.35%
$5.67
ADD
-25.47%
$0.05
HIMS
-5.75%
$59.15
AUUD
+0.97%
$2.06
SOND
+79.34%
$1.65
BAC
-4.03%
$50.17
CRWV
+1.79%
$141.74
JOBY
-8.69%
$16.07
SLNH
-2.33%
$4.19
IONQ
-9.41%
$65.59
TOVX
-48.67%
$0.43
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.